AR099914A1 - Derivados de indol y de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen - Google Patents
Derivados de indol y de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienenInfo
- Publication number
- AR099914A1 AR099914A1 ARP140102679A ARP140102679A AR099914A1 AR 099914 A1 AR099914 A1 AR 099914A1 AR P140102679 A ARP140102679 A AR P140102679A AR P140102679 A ARP140102679 A AR P140102679A AR 099914 A1 AR099914 A1 AR 099914A1
- Authority
- AR
- Argentina
- Prior art keywords
- branched
- linear
- group
- alkyl
- cycloalkyl
- Prior art date
Links
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical class C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 title 1
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 12
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 9
- 125000003118 aryl group Chemical group 0.000 abstract 8
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 125000004432 carbon atom Chemical group C* 0.000 abstract 7
- 125000005843 halogen group Chemical group 0.000 abstract 7
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 7
- 125000001072 heteroaryl group Chemical group 0.000 abstract 6
- 229910052757 nitrogen Inorganic materials 0.000 abstract 5
- 125000006684 polyhaloalkyl group Polymers 0.000 abstract 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 3
- 125000000304 alkynyl group Chemical group 0.000 abstract 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 3
- 125000005842 heteroatom Chemical group 0.000 abstract 3
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 239000001301 oxygen Substances 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 239000011593 sulfur Substances 0.000 abstract 3
- -1 - NR7R7 Chemical group 0.000 abstract 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000002619 bicyclic group Chemical group 0.000 abstract 2
- 150000001768 cations Chemical class 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000002950 monocyclic group Chemical group 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 125000005605 benzo group Chemical group 0.000 abstract 1
- 125000002527 bicyclic carbocyclic group Chemical group 0.000 abstract 1
- 235000010290 biphenyl Nutrition 0.000 abstract 1
- 239000004305 biphenyl Substances 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 abstract 1
- 125000001620 monocyclic carbocycle group Chemical group 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000003003 spiro group Chemical group 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
Reivindicación 1: Compuesto de fórmula (1) en la que: W representa un grupo C-A³ o un átomo de nitrógeno; A¹, A² y A³ representan independientemente los unos de los otros un átomo de hidrógeno o de halógeno, un polihalógenoalquilo C₁₋₆ lineal o ramificado, un grupo alquilo C₁₋₆ lineal o ramificado o un cicloalquilo, o bien A¹ y A² forman con los átomos de carbono a los que están unidos un cicloalquilo o un ciclo benzo, estando estos dos grupos sustituidos opcionalmente con un átomo de halógeno, un grupo alquilo C₁₋₆ lineal o ramificado, polihalógenoalquilo C₁₋₆ lineal o ramificado, hidroxi, alcoxi C₁₋₆ lineal o ramificado o -COOH, entendiéndose que W representa necesariamente un grupo C-A³ cuando A¹ y A² representan independientemente el uno del otro un átomo de hidrógeno o de halógeno, un polihalógenoalquilo C₁₋₆ lineal o ramificado, un grupo alquilo C₁₋₆ lineal o ramificado o un cicloalquilo; T representa un átomo de hidrógeno, un grupo alquilo C₁₋₆ lineal o ramificado sustituido opcionalmente con uno a tres átomos de halógeno, un grupo alquil C₁₋₄-NR¹R², o un grupo alquil C₁₋₄-OR⁶; R¹ y R² representan independientemente el uno del otro un átomo de hidrógeno o un grupo alquilo C₁₋₆ lineal o ramificado, o bien R¹ y R² forman con el átomo de nitrógeno al que están unidos un heterocicloalquilo; R³ representa un grupo alquilo C₁₋₆ lineal o ramificado, alquenilo C₂₋₆ lineal o ramificado, alquinilo C₂₋₆ lineal o ramificado, cicloalquilo, cicloalquil C₃₋₁₀alquilo C₁₋₆ lineal o ramificado, heterocicloalquilo, arilo o heteroarilo, entendiéndose que uno o varios átomos de carbono de los grupos anteriores, o átomos de carbono de sus posibles sustituyentes, puede(n) estar deuterado(s); R⁴ representa un grupo arilo, heteroarilo, cicloalquilo, alquilo C₁₋₆ lineal o ramificado, entendiéndose que uno o varios átomos de carbono de los grupos anteriores, o átomos de carbono de sus posibles sustituyentes, puede(n) estar deuterado(s); R⁵ representa un átomo de hidrógeno o de halógeno, un grupo alquilo C₁₋₆ lineal o ramificado, o un grupo alcoxi C₁₋₆ lineal o ramificado; R⁶ representa un átomo de hidrógeno o un grupo alquilo C₁₋₆ lineal o ramificado; Rᵃ, Rᵇ, Rᶜ y Rᵈ representan independientemente los unos de los otros R⁷, un átomo de halógeno, un grupo alcoxi C₁₋₆ lineal o ramificado, un grupo hidroxi, un grupo polihalógenoalquilo C₁₋₆ lineal o ramificado, un grupo trifluorometoxi, -NR⁷R⁷, nitro, R⁷-CO-alquil C₀₋₆-, R⁷-CO-NH-alquil C₀₋₆-, NR⁷R⁷-CO-alquil C₀₋₆-, NR⁷R⁷-CO-alquil C₀₋₆-O-, R⁷-SO₂-NH-alquil C₀₋₆-, R⁷-NH-CO-NH-alquil C₀₋₆-, R⁷-O-CO-NH-alquil C₀₋₆-, un grupo heterocicloalquilo, o bien los sustituyentes de una de las parejas (Rᵃ, Rᵇ), (Rᵇ, Rᶜ) o (Rᶜ, Rᵈ) forman junto con los átomos de carbono a los que están unidos un ciclo constituido por 5 a 7 eslabones, que puede contener de uno a 2 heteroátomos elegidos entre oxígeno y azufre, entendiéndose también que uno o varios átomos de carbono del ciclo definido anteriormente puede(n) estar deuterado(s) o sustituidos con uno a 3 grupos elegidos entre halógeno o alquilo C₁₋₆ lineal o ramificado; R⁷ y R⁷, representan independientemente el uno del otro un hidrógeno, un grupo alquilo C₁₋₆ lineal o ramificado, alquenilo C₂₋₆ lineal o ramificado, alquinilo C₂₋₆ lineal o ramificado, arilo o un heteroarilo, o bien R⁷ y R⁷ forman junto con el átomo de nitrógeno al que están unidos un heterociclo constituido por 5 a 7 eslabones; entendiéndose que cuando el compuesto de fórmula (1) contiene un grupo hidroxi, este último puede estar sustituido opcionalmente con uno de los grupos siguientes: -PO(OM)(OM), -PO(OM)(O⁻M₁⁺), -PO(O⁻M₁⁺)(O⁻M₂⁺), -PO(O⁻)(O⁻)M₃²⁺, -PO(OM)(O[CH₂CH₂O]ₙCH₃), o -PO(O⁻M₁⁺)(O[CH₂CH₂O]ₙCH₃), en los que M y M representan independientemente el uno del otro un átomo de hidrógeno, un grupo alquilo C₁₋₆ lineal o ramificado, un grupo alquenilo C₂₋₆ lineal o ramificado, un grupo alquinilo C₂₋₆ lineal o ramificado, un cicloalquilo o un heterocicloalquilo, los dos constituidos por 5 a 6 eslabones, mientras que M₁⁺ y M₂⁺ representan independientemente el uno del otro un catión monovalente farmacéuticamente aceptable, M₃²⁺ representa un catión divalente farmacéuticamente aceptable y n es un número entero comprendido entre 1 y 5; entendiéndose también que: por arilo, se entiende un grupo fenilo, naftilo, bifenilo o indenilo; por heteroarilo, se entiende cualquier grupo mono o bicíclico constituido por 5 a 10 eslabones, que posee al menos una parte aromática y que contiene de 1 a 4 heteroátomos elegidos entre oxígeno, azufre o nitrógeno (incluyendo los nitrógenos cuaternarios); por cicloalquilo, se entiende cualquier grupo carbocíclico no aromático, mono o bicíclico, que contiene 3 a 10 eslabones; por heterocicloalquilo, se entiende cualquier grupo no aromático mono o bicíclico que contiene 3 a 10 eslabones y que contiene 1 a 3 heteroátomos elegidos entre oxígeno, azufre, SO, SO₂ o nitrógeno, pudiendo estar sustituidos los grupos arilo, heteroarilo, cicloalquilo y heterocicloalquilo así definidos y los grupos alquilo, alquenilo, alquinilo, alcoxi, con 1 a 3 grupos elegidos entre alquilo C₁₋₆ lineal o ramificado sustituido opcionalmente, espiro C₃₋₆, alcoxi C₁₋₆ lineal o ramificado sustituido opcionalmente, alquil C₁₋₆-S-, hidroxi, oxo (o N-óxido llegado el caso), nitro, ciano, -COOR, -OCOR, NRR, polihalógenoalquilo C₁₋₆ lineal o ramificado, trifluorometoxi, alquil C₁₋₆sulfonilo, halógeno, arilo sustituido opcionalmente, heteroarilo, ariloxi, aril-S-, cicloalquilo, heterocicloalquilo sustituido opcionalmente con uno o varios átomos de halógeno o grupos alquilos, entendiéndose que R y R representan, independientemente el uno del otro, un átomo de hidrógeno o un grupo alquilo C₁₋₆ lineal o ramificado sustituido opcionalmente; sus enantiómeros y diastereoisómeros, así como sus sales de adición a un ácido o a una base farmacéuticamente aceptable.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1357277A FR3008978A1 (fr) | 2013-07-23 | 2013-07-23 | "nouveaux derives d'indole et de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent" |
Publications (1)
Publication Number | Publication Date |
---|---|
AR099914A1 true AR099914A1 (es) | 2016-08-31 |
Family
ID=49911607
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP140102679A AR099914A1 (es) | 2013-07-23 | 2014-07-21 | Derivados de indol y de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen |
Country Status (31)
Country | Link |
---|---|
US (2) | US9765056B2 (es) |
EP (2) | EP3027602B1 (es) |
JP (1) | JP6458028B2 (es) |
KR (1) | KR102337149B1 (es) |
CN (1) | CN105408321B (es) |
AR (1) | AR099914A1 (es) |
AU (1) | AU2014294866B2 (es) |
BR (1) | BR112016001333B1 (es) |
CA (1) | CA2917965C (es) |
CY (1) | CY1120475T1 (es) |
DK (1) | DK3027602T3 (es) |
EA (1) | EA028609B1 (es) |
ES (1) | ES2687475T3 (es) |
FR (1) | FR3008978A1 (es) |
HK (1) | HK1218753A1 (es) |
HR (1) | HRP20181333T1 (es) |
HU (1) | HUE039507T2 (es) |
LT (1) | LT3027602T (es) |
MX (1) | MX364479B (es) |
NZ (1) | NZ715847A (es) |
PL (1) | PL3027602T3 (es) |
PT (1) | PT3027602T (es) |
RS (1) | RS57545B1 (es) |
RU (1) | RU2693404C2 (es) |
SG (1) | SG11201600004SA (es) |
SI (1) | SI3027602T1 (es) |
TW (1) | TW201504224A (es) |
UA (1) | UA117020C2 (es) |
UY (1) | UY35653A (es) |
WO (1) | WO2015011396A1 (es) |
ZA (1) | ZA201600415B (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105237509A (zh) * | 2015-11-20 | 2016-01-13 | 江苏瑞邦农药厂有限公司 | 一种2,2-二氟-1,3-苯并二恶茂的合成方法 |
EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
WO2017197036A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
CA3049728A1 (en) * | 2017-01-10 | 2018-07-19 | Eth Zurich | Inhibitors of g-protein-coupled receptor kinase 2 and their use |
US11530254B2 (en) | 2017-03-31 | 2022-12-20 | The University Of Tokyo | Norovirus antibody |
CN108409580A (zh) * | 2018-02-01 | 2018-08-17 | 浙江工业大学 | 一种苄胺类化合物的合成方法 |
CN113453679A (zh) | 2018-12-20 | 2021-09-28 | C4医药公司 | 靶向蛋白降解 |
WO2023225359A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Antibody-drug conjugates of antineoplastic compounds and methods of use thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070060596A1 (en) | 2003-10-24 | 2007-03-15 | Giblin Gerard M P | Heterocyclyl compounds |
TW200533398A (en) * | 2004-03-29 | 2005-10-16 | Bristol Myers Squibb Co | Novel therapeutic agents for the treatment of migraine |
CA2577752A1 (en) * | 2004-08-20 | 2006-03-02 | The Regents Of The University Of Michigan | Small molecule inhibitors of anti-apoptotic bcl-2 family members and the uses thereof |
GB0522908D0 (en) | 2005-11-10 | 2005-12-21 | Merck Sharp & Dohme | Therapeutic agents |
EP2714681B1 (en) * | 2011-05-25 | 2015-06-24 | Bristol-Myers Squibb Company | Substituted sulfonamides useful as antiapoptotic bcl inhibitors |
EP2794592A1 (en) * | 2011-12-23 | 2014-10-29 | Novartis AG | Compounds for inhibiting the interaction of bcl2 with binding partners |
AU2012355613A1 (en) * | 2011-12-23 | 2014-07-17 | Novartis Ag | Compounds for inhibiting the interaction of BCL2 with binding partners |
JP2015503516A (ja) * | 2011-12-23 | 2015-02-02 | ノバルティス アーゲー | Bcl2と結合相手の相互作用を阻害するための化合物 |
EP2794591A1 (en) * | 2011-12-23 | 2014-10-29 | Novartis AG | Compounds for inhibiting the interaction of bcl2 with binding partners |
JP2015503517A (ja) * | 2011-12-23 | 2015-02-02 | ノバルティス アーゲー | Bcl2と結合相手の相互作用を阻害するための化合物 |
FR2986002B1 (fr) | 2012-01-24 | 2014-02-21 | Servier Lab | Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
-
2013
- 2013-07-23 FR FR1357277A patent/FR3008978A1/fr not_active Withdrawn
-
2014
- 2014-07-08 UY UY35653A patent/UY35653A/es unknown
- 2014-07-21 AR ARP140102679A patent/AR099914A1/es unknown
- 2014-07-22 HU HUE14758604A patent/HUE039507T2/hu unknown
- 2014-07-22 CA CA2917965A patent/CA2917965C/fr active Active
- 2014-07-22 ES ES14758604.4T patent/ES2687475T3/es active Active
- 2014-07-22 WO PCT/FR2014/051884 patent/WO2015011396A1/fr active Application Filing
- 2014-07-22 UA UAA201601398A patent/UA117020C2/uk unknown
- 2014-07-22 TW TW103125162A patent/TW201504224A/zh unknown
- 2014-07-22 EP EP14758604.4A patent/EP3027602B1/fr active Active
- 2014-07-22 RS RS20180839A patent/RS57545B1/sr unknown
- 2014-07-22 RU RU2016106002A patent/RU2693404C2/ru active
- 2014-07-22 BR BR112016001333-6A patent/BR112016001333B1/pt active IP Right Grant
- 2014-07-22 EA EA201600121A patent/EA028609B1/ru unknown
- 2014-07-22 LT LTEP14758604.4T patent/LT3027602T/lt unknown
- 2014-07-22 DK DK14758604.4T patent/DK3027602T3/en active
- 2014-07-22 US US14/905,877 patent/US9765056B2/en active Active
- 2014-07-22 AU AU2014294866A patent/AU2014294866B2/en active Active
- 2014-07-22 SI SI201430784T patent/SI3027602T1/en unknown
- 2014-07-22 KR KR1020167004577A patent/KR102337149B1/ko active IP Right Grant
- 2014-07-22 JP JP2016528587A patent/JP6458028B2/ja active Active
- 2014-07-22 PT PT147586044T patent/PT3027602T/pt unknown
- 2014-07-22 PL PL14758604T patent/PL3027602T3/pl unknown
- 2014-07-22 NZ NZ715847A patent/NZ715847A/en unknown
- 2014-07-22 MX MX2016000900A patent/MX364479B/es active IP Right Grant
- 2014-07-22 EP EP16201228.0A patent/EP3168217A1/fr not_active Withdrawn
- 2014-07-22 CN CN201480041559.7A patent/CN105408321B/zh active Active
- 2014-07-22 SG SG11201600004SA patent/SG11201600004SA/en unknown
-
2016
- 2016-01-12 ZA ZA2016/00415A patent/ZA201600415B/en unknown
- 2016-06-13 HK HK16106759.0A patent/HK1218753A1/zh unknown
-
2017
- 2017-08-14 US US15/676,154 patent/US10662173B2/en active Active
-
2018
- 2018-07-19 CY CY20181100757T patent/CY1120475T1/el unknown
- 2018-08-22 HR HRP20181333TT patent/HRP20181333T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR099914A1 (es) | Derivados de indol y de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
AR097008A1 (es) | Derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
AR099913A1 (es) | Derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
AR123048A2 (es) | Moduladores de p2x7 | |
AR108812A1 (es) | Proceso para preparar un derivado de piridona policíclica sustituida y cristal del mismo | |
AR105103A1 (es) | Derivados hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
AR098906A1 (es) | Derivados de tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
AR093505A1 (es) | Derivados de 5-fluoro-n-(piridin-2-il)piridin-2-amina que contienen un grupo sulfoximina | |
AR112834A1 (es) | Derivados de rapamicina | |
AR091498A1 (es) | DERIVADOS DE 2,3-DIHIDRO-1H-IMIDAZO{1,2-a}PIRIMIDIN-5-ONA Y 1,2,3,4-TETRAHIDRO-PIRIMIDO{1,2-a}PIRIMIDIN-6-ONA QUE CONTIENEN UNA MORFOLINA SUSTITUIDA, SU PREPARACION Y SU UTILIZACION FARMACEUTICA | |
AR105102A1 (es) | Derivados bicíclicos, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
AR106472A1 (es) | Inhibidores de acc y usos de los mismos | |
AR092742A1 (es) | Piridinonas antifibroticas | |
AR105104A1 (es) | Derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
AR092108A1 (es) | Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn | |
AR092349A1 (es) | Imidazotriazincarbonitrilos utiles como inhibidores de quinasa | |
AR098337A1 (es) | Triazolopirazina | |
AR093504A1 (es) | 4-(orto)-fluorofenil-5-fluoropirimidin-2-ilaminas que contienen un grupo sulfoximina como inhibidores de cdk9, un intermediario para su sintesis y metodos de obtencion de ambos compuestos | |
AR103742A1 (es) | Derivados de trifluorometilpropanamida | |
AR098517A1 (es) | Compuestos derivados de octahidro-ciclobuta[1,2-c;3,4-c]dipirrol-2-ilo | |
AR074021A1 (es) | Compuestos heterociclicos fusionados como moduladores del canal ionico | |
AR090572A1 (es) | Derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos | |
ES2626801T3 (es) | Compuestos de triazolopiridina como inhibidores de pde10a | |
AR097435A1 (es) | 6-alquinilpiridinas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |